Economic and Developmental Considerations for Pharmacogenomic Technology

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.24, Iss.4, 2006-01, pp. : 335-343

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacogenomic considerations for immunosuppressive therapy

By Yagil Yoram Yagil Chana

Pharmacogenomics, Vol. 4, Iss. 3, 2003-05 ,pp. : 309-319

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomic considerations of the paraoxonase polymorphisms

By Furlong Clement E Cole Toby B Jarvik Gail P Costa Lucio G

Pharmacogenomics, Vol. 3, Iss. 3, 2002-05 ,pp. : 341-348

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomic considerations in drug delivery

By Attar Mayssa Lee Vincent HL

Pharmacogenomics, Vol. 4, Iss. 4, 2003-07 ,pp. : 443-461

Future Medicine

Access to resources Recommend Favorite

Angiotensin II receptor polymorphisms in hypertension. Pharmacogenomic considerations

By Baudin Bruno

Pharmacogenomics, Vol. 3, Iss. 1, 2002-01 ,pp. : 65-73

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomic considerations of xenograft mouse models of acute leukemia

By Guihard Soizic Peyrouze Pauline Cheok Meyling H

Pharmacogenomics, Vol. 13, Iss. 15, 2012-11 ,pp. : 1759-1772

Future Medicine

Access to resources Recommend Favorite